STOCK TITAN

Gritstone bio, Inc. - GRTS STOCK NEWS

Welcome to our dedicated page for Gritstone bio news (Ticker: GRTS), a resource for investors and traders seeking the latest updates and insights on Gritstone bio stock.

Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology leader developing novel immunotherapies and vaccines for cancer and infectious diseases. This dedicated news hub provides investors and researchers with essential updates on the company’s pioneering work in neoantigen-targeting platforms and self-amplifying mRNA technology.

Access real-time announcements including clinical trial results, regulatory milestones, and strategic collaborations. Our curated collection features:

• Clinical development updates for GRANITE and SLATE vaccine programs
• Technology innovations in AI-driven EDGE platform and samRNA vectors
• Partnership announcements with leading research institutions
• Peer-reviewed data publications and conference presentations

Bookmark this page for streamlined tracking of Gritstone bio’s progress in advancing personalized cancer vaccines and next-generation infectious disease solutions. All content is sourced directly from company filings and verified industry channels.

Rhea-AI Summary

Gritstone bio, Inc. (Nasdaq: GRTS) appointed Stephen Webster, a finance executive with 30 years of experience, to its Board of Directors. Webster's expertise in raising capital and business development will be important as the company prepares for Phase 2 GRANITE data and potential growth. Steve Krognes will not stand for re-election at the 2024 Annual Meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Nature Medicine publishes interim results from Gritstone bio's Phase 1/2 study of 'Off-the-Shelf' Neoantigen Vaccine Platform (SLATE), highlighting the development of a more potent KRAS-specific vaccine candidate, SLATE-KRAS, and the importance of antigen selection and cassette design in neoantigen-directed immunotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.9%
Tags
-
Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) announces participation in upcoming investor and scientific conferences to showcase its innovative personalized cancer vaccines. The events will feature presentations and panels discussing clinical trial results and advancements in cancer vaccine technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.12%
Tags
conferences
Rhea-AI Summary
Gritstone Bio, Inc. updates its EDGE platform at AACR Annual Meeting, showcasing improved prediction accuracy for HLA Class I and II epitopes. EDGE, combined with vaccine vectors, shows potential in identifying neoantigens for robust immunity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.12%
Tags
none
-
Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) announced a $32.5 million public offering of common stock and warrants, aiming to raise capital for its vaccine development efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-48.94%
Tags
-
Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) initiates a public offering of common stock and warrants underwritten by TD Cowen and Evercore ISI. The offering, subject to market conditions, aims to raise capital for the development of potent vaccines. The company plans to offer shares, pre-funded warrants, and common warrants, with details available on the SEC's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-48.94%
Tags
Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) announces positive preliminary data from Phase 2 study of GRANITE, a personalized neoantigen cancer vaccine, in metastatic colorectal cancer patients. Early PFS trends show benefit for GRANITE recipients, with a high-risk group showing a 48% relative risk reduction in progression or death. Mature PFS data expected in Q3 2024 and overall survival data in 1H 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-48.94%
Tags
-
Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) reported financial results for Q4 2023, highlighting key developments in their oncology and infectious disease programs. The company is expecting preliminary data from the Phase 2 study of their personalized cancer vaccine, GRANITE, in 1Q 2024. They are also preparing to launch a Phase 2b study for their COVID-19 vaccine in Fall 2024. Gritstone's cash position stood at $86.9 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.86%
Tags
-
Rhea-AI Summary
Gritstone bio, Inc. (Nasdaq: GRTS) announces a 40% reduction in workforce due to delayed funding for the CORAL Phase 2b study. CEO Andrew Allen expresses gratitude to departing employees while emphasizing commitment to ongoing programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-27.86%
Tags
none
Rhea-AI Summary
Gritstone bio, Inc. (GRTS) announces participation in key investor and scientific conferences to discuss breakthroughs in vaccine pipeline and leveraging AI for immunotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
conferences
Gritstone bio, Inc.

Nasdaq:GRTS

GRTS Rankings

GRTS Stock Data

3.80M
118.11M
1.91%
29.03%
6.37%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
EMERYVILLE